Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

BMS’ Opdivo wins EU approval for second-line oesophageal cancer Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD) blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... In this study, Keytruda plus chemotherapy demonstrated a median overall survival rate of 12.4 months versus 9.8

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer According to Merck and Eisai, when administered alongside Lenvima, Keytruda demonstrated a statistically significant and clinically meaningful improvement on all counts – including PFS, OS and ORR. ... Merck already has approval for another combination

Moderna posts encouraging early data for personalised cancer vaccine

Moderna posts encouraging early data for personalised cancer vaccine Vaccine tested alongside Merck's Keytruda. Ahead of a key data read-out for its COVID-19 vaccine, Moderna has posted positive early data from an interim analysis of its ongoing ... The vaccine, mRNA-4157, is being evaluated in combination with Merck

Keytruda growth helps Merck to offset COVID-19 impact in Q3

Keytruda growth helps Merck to offset COVID-19 impact in Q3 The growth in profits was mainly due to increasing demand for certain drugs, including its blockbuster checkpoint inhibitor Keytruda (pembrolizumab), and its bacterial pneumonia vaccine. ... In the third quarter, sales of Keytruda grew by 24% to $2.2bn

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC This means it beats a number of competitors to the punch – including Merck &Co’s Keytruda (pembrolizumab), Roche’s Tecentriq (atezolizumab) and AstraZeneca’s Imfinzi (durvalumab), which are all studying their ... Although Keytruda holds much of

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics